The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades. The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents. Samples are gathered in primary care setting.
Study Type
OBSERVATIONAL
Enrollment
168
Vestre Viken Hospital Trust
Bærum, Norway
University Hospital Akershus
Lørenskog, Norway
Unilabs
Skien, Norway
Helse Stavanger HF
Stavanger, Norway
Number of days until symptomatic resolution
Number of days from the start of treatment that the patient feels completely free of urinary tract symptoms Number of days after start of antibiotic treatment with mecillinam when the patient feels free of symptoms from the urinary tract
Time frame: Two weeks after finishing the primary antibiotic treatment
Number of patients with ESBL producing bacteria detected in a urine sample taken two weeks after finishing initial treatment
Time frame: Two weeks after end of initial treatment
Number of patients who received a second treatment regime in the follow-up period
Number of patients who received a secondary antibiotic treatment to obtain clinical cure.
Time frame: 2 weeks after end of initial treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital of North Norway
Tromsø, Norway
St Olavs Hospital
Trondheim, Norway
Vestfold Hospital Trust
Tønsberg, Norway